AYTU BIOPHARMA INC

Note1 - Nature of Business, Financial Condition, Basis of Presentation

Aytu BioPharma, Inc. (“Aytu”, or the “Company”), is a pharmaceutical company focused on commercializing novel therapeutics. The Company operates throughtwo business segments (i) the Rx Segment, consisting of prescription pharmaceutical products sold primarily throughthird party wholesalers and (ii) the Consumer Health Segment, which consists of various consumer healthcare products sold directly to consumers (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on* August 9, 2002,in the State of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015.Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (*the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc.

On* January 6, 2023,the Company effected a reverse stock split in which each common stockholder receivedone* share of common stock for every twenty shares held (the “Reverse Stock Split”). All share and per share amounts in this quarterly report have been adjusted to reflect the effect of the Reverse Stock Split.

The Rx Segment primarily consists oftwo product portfolios. First the ADHD Portfolio, which consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”). Second the Pediatric Portfolio, which consists of Poly-Vi-Flor and Tri-Vi-Flor,two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.

The Consumer Health Segment consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. To date, the Consumer Health Segment has generated negative cash flows. In fiscal2023, the Company announced it would wind down the Consumer Health Segment in fiscal2024.

The Company’s strategy is to continue building its portfolio of revenue-generating prescription pharmaceutical products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating products and generating profitability, in fiscal2023, the Company indefinitely suspended active development of its clinical development programs includingAR101 (enzastaurin) and terminated the license agreements relating to Healight andNT0502 (N-desethyloxybutynin).

As of* December 31, 2023*, the Company had $19.5 million of cash and cash equivalents and $29.4 million of accounts receivable. The Company’s operations have historically consumed cash and* maycontinue to consume cash in the future. The Company had a net loss of $0.2 million and $8.3 million during thethree* andsix months ended* December 31, 2023,respectively. The Company had an accumulated deficit of $312.5 million and $304.1 million as of December 31, 2023* and* June 30, 2023*, respectively. Cash used in operations was$0.4 million and $11.6 million during thesix months ended* December 31, 2023and2022*, respectively.

In addition, the Company has non-operating liabilities that are scheduled to, or* maybecome, current in thetwelve* months following the filing of this Form10-Q, most notably the maturity of the $15 million Avenue Capital term note (the “Avenue Note”) as discussed further inNote11* - Long-term Debt*. The Company expects to refinance the Avenue Note, however, there areno assurances the Company will be able to refinance the Avenue Note. As a result of this, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements donot include adjustments that might be necessary if the Company is unable to continue as a going concern.

8

Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on (i) improving cash flows from operations, (ii) winding down the Consumer Health Segment, (iii) refinancing its $15 million Avenue Note to extend its maturity date, and, (iv), if necessary, raising additional capital through public or private equity offerings, debt offerings, or monetizing additional assets in order to meet its obligations. Management believes that the Company has adequate access to capital resources. However, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it* maybe required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses mayadversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can beno* assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.

Basis of Presentation. The unaudited consolidated financial statements contained in this Form10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements should be read in conjunction with the Company’s2023 Form10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of* June 30, 2023*, was derived from the audited annual financial statements but doesnot contain all of the footnote disclosure from the annual financial statements. The results of operations for the period ended* December 31, 2023* arenot necessarily indicative of expected operating results for the full year or any future period.

Prior Period Reclassification. Certain prior year amounts in the consolidated statements of operations have been reclassified to conform to the current year presentation, including a reclassification of the fair value adjustment from contingent consideration. Net gain or loss from the fair value of contingent consideration was previously included in other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. This reclassification didnot impact net loss or cash flows for thethree orsix months ended* December 31, 2023and2022* or the Company’s financial position as of* December 31, 2023* or* June 30, 2023*.

Note2 - Significant Accounting Policies

Use of Estimates

Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, butnot limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results* may*differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic480, Distinguishing Liabilities from Equity (“ASC480”) and ASC Topic815, Derivatives and Hedging (“ASC815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC480, meet the definition of a liability pursuant to ASC480, and whether the warrants meet all of the requirements for equity classification under ASC815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.

9

Income Taxes

The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have beenno changes in tax law affecting the tax provision during thethree andsix months ended* December 31, 2023*. The effective tax rate was 136.2% and negative 11.0% for thethree andsix months ended* December 31, 2023*, respectively, primarily driven by the limitations on losses as a result of Section382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. The effective tax rate was 0% for both thethree andsix months ended* December 31, 2022,respectively, reflecting the full valuation allowance andno* impact of Section382 of the Internal Revenue Code.

An ownership change could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation* mayoffset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the pastfive* years have caused a significant limitation on the Company's ability to use the pre-acquisition net operating loss carryovers. The ownership changes could result in increased future tax liability and are a driver of the change from azero percent effective tax rate.

Employee Retention Credit

On* March 27, 2020,the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to70%* of the qualified wages paid to employees after* December 31, 2020through September 30, 2021.*The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic.

As there isno authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (“IAS”)20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS20”). In accordance with IAS20, when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall be recognized as other income in the consolidated statement of operations (seeNote -9 Other Liabilities).

Recently Adopted Accounting Pronouncements

Financial Instruments –*** Credit Losses.*** In* June2016,* the FASB issued ASU2016-13,Financial Instruments – Credit Losses* (“ASU2016-13”) requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after* December15,* 2019. However, in* October2019,* the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after* December*15,* 2022. The effective dates for the amendments in ASU2022-02 align with those of ASU2016-13. The Company adopted ASU2016-13 and ASU2019-05 on* July 1, 2023.The Company evaluated the impact of adoption of ASUs2016*-13, 2019-05, and2022-02 and concluded that the application of the new standards didnot have a material impact on the Company’s consolidated financial statements.

Recent Accounting PronouncementsNot Yet Adopted

Debt -Debt with Conversion and Other Options. In* August 2020,the FASB issued ASUNo.* 2020-06,* Debt*—Debt with Conversion and Other Options (Subtopic470*-20) and Derivatives and Hedging*—* Contracts in Entity*’s Own Equity (Subtopic815*-40)— Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument withno separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023,including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024and doesnot* expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.

10

Segment Reporting - Improvements to Reportable Segment Disclosures. In November 2023,the FASB issued ASUNo. 2023-07, Segment Reporting (Topic280*): Improvements to Reportable Segment Disclosures* (“ASU2023-07”). ASU2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU2023-07 is effective for fiscal years beginning after* December 15, 2023,and interim periods in fiscal years beginning after December 15, 2024.*Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company’s consolidated financial statements and disclosures.

For a complete set of the Company’s significant accounting policies, refer to the Company's2023 Form10-K. Other than the application of IAS20 for the ERC, there have beenno significant changes to the Company’s significant accounting policies during thesix months ended* December 31, 2023*.

Note3 - Revenues from Contracts with Customers

Net product revenue in the Rx Segment consists of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net product revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, consistent with contractual terms.

The Company generates Consumer Health Segment revenue from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, consistent with contractual terms and aligning with the transfer of control of the products. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost, and are included in cost of sales.

Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which* mayvary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may**not* follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company continually monitors these provisions and doesnot believe variances between actual and estimated amounts have been or will be material.

Revenues by Segment.** Net product revenue disaggregated by segment for thethree andsix months ended December 31, 2023and2022 were as follows:

11

Revenues by Product Portfolio.** Net product revenue disaggregated by significant product portfolio in the Rx Segment for thethree andsix months ended December 31, 2023and2022 were as follows:

Other includes discontinued products in the Rx Segment. The Consumer Health Segment is comprised ofone product portfolio, the Consumer Health Portfolio.

Revenues by Geographic location. The Company’s revenues are predominately within the United States, with insignificant sales internationally.

Note4 - Inventories

Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on afirst-in,first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there areno alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the periodfirst recognized. The Company incurred inventory write-downs of $0.1 million andzero for each of thethree months ended* December 31, 2023and2022*, respectfully, and $0.1 million for each of thesix months ended* December 31, 2023and2022*.

Inventory balances consist of the following:

Note5 - Property and Equipment

Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term.

12

Property and equipment consist of the following:

Depreciation and amortization expense from property and equipment was $0.3 million and $0.4 million for thethree months ended* December 31, 2023and2022*, respectfully, and $0.6 million and $0.7 million for thesix months ended* December 31, 2023and2022*, respectively.

Note6 - Leases

The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between fiscal2024 and fiscal2029. Most leases includeone or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally donot contain any material residual value guarantees or material restrictive covenants.

In* May 2023,the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in September 2023 (lease commencement) with an initial term offive and a half years. The Company recorded an operating lease right-of-use (“ROU”) asset of $0.7 million and a lease liability of $0.7 million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of 10.3%. The Company utilized the practical expedient tonot* separate lease and non-lease components upon recognition.

The components of lease expenses are as follows:

13

Supplemental balance sheet information related to leases is as follows:

Remaining lease term and discount rate used are as follows:

Supplemental cash flow information related to lease is as follows:

As of* December 31, 2023*, the maturities of the Company’s future minimum lease payments were as follows:

14

Note7 - Intangible Assets

The following table provides the summary of the Company’s intangible assets as of* December 31, 2023* and* June 30, 2023*, respectively. Carrying amounts are net of any impairment charges from prior periods. An intangible asset withzero net carrying amount at the end of a reporting period isnot presented in the table of a future reporting period.

The following table summarizes the estimated future amortization expense to be recognized over the nextfive fiscal years and periods thereafter:

Acquired Product Technology Rights

The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in* November 2019and the Neos Acquisition in March 2021.*

15

Karbinal ER. The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal ER in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in* Augustof2033,* with an optional additional 20-year extension.

Poly-Vi-Flor and Tri-Vi-Flor. The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.

ADHD Portfolio. As part of the Neos Acquisition, the Company acquired product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years.

Acquired Technology Right

TRRP Technology. As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlies the ADHD portfolio and can potentially be used in future product development initiatives as well.

Acquired Product Distribution Rights (and customer list)

In connection with the Innovus Acquisition, the Company obtained35 products with a combination of over300 registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During thefourth quarter of fiscal2023, the acquired product distribution rights incurred an impairment charge of $3.0 million due to the discontinuation of products in the Consumer Health Segment.

Acquired In-Process R&D

IPR&D–* NT0502. As part of the Neos Acquisition, the Company acquired in-process research and development associated withNT0502,* a new chemical entity being developed for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&D will begin amortizing on a straight-line basis over the life of the product. During fiscal2023, the Company terminated its development program ofNT0502. As a result, the Company fully impaired the IPR&D ofNT0502, recording impairment expense of $2.6 million to its Rx Segment during thethree months ended* December 31, 2022.*

Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.6 million and $1.5 million for thethree months ended* December 31, 2023and2022*, respectively, and $3.3 million and $3.0 million for thesix months ended* December 31, 2023and2022*, respectively.

16

Note8 - Accrued Liabilities

Accrued liabilities consist of the following:

Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals,none of which individually or in the aggregate represent greater thanfive percent of total liabilities.

Note9 - Other Liabilities

Fixed Payment Arrangements

Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in2019, including fixed and variable payments.

17

The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from* August1* through* July31,* of 70,000 units annually through2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in* Augustof each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, thefirst* of which is triggered at $40.0 million of net revenues. As of* December 31, 2023*, the fixed payment arrangement balance was $1.8 million in other current liabilities, and $1.2 million in other non-current liabilities on the consolidated balance sheet.

On* May 12, 2022,the Company entered into an agreement with Tris to terminate the Tuzistra XR License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced its total liability for minimum payments by approximately $8.0 million from the original License Agreement. As of December 31, 2023*, the balance was $6.0 million in other current liabilities on the consolidated balance sheet.

Operating Lease Liabilities

The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer toNote6* - Leases* for further detail.

Employee Retention Credit

The $3.8 million ERC accrual in other non-current liabilities as of* December 31, 2023*, represents the proceeds the Company received from the ERC program during thefirst quarter of fiscal2024. The ERC is a refundable payroll tax credit from the CARES Act enacted by the U.S. government to provide certain relief from the COVID-19 pandemic. The refundable payroll tax credit shall be recognized in the consolidated statement of operations following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Service (seeNote2* – Significant Accounting Policies*). The associated vendor fee of $0.4 million was expensed as incurred in thefirst quarter of fiscal2024.

Other

Other consists of taxes payable and deferred cost related to the Company’s technology transfer.

Note10 - Line of Credit

The Company has entered into a secured credit agreement, as amended, with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $14.0 million, less a $3.5 million availability block, in secured revolving loans (the “Revolving Loans”), against 85% of eligible accounts receivable. The Revolving Loans thereunder, accrue at variable interest through maturity at theone-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement includes an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The maturity date under the Eclipse Loan Agreement is* January 26, 2025.*

In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i)1.0% of the Revolving Loans commitment if such event occurs after* January 26, 2023but on or before January 26, 2024,and (ii)0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024but on or before January 26, 2025.The Company maypermanently terminate the Eclipse Loan Agreement at any time with at leastfive* business days prior notice to Eclipse.

The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of* December 31, 2023*, the Company was in compliance with the covenants under the Eclipse Loan Agreement.

18

The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with afirst priority lien in favor of Eclipse on the ABL Priority Collateral, and asecond priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement.

Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $23.2 thousand and $176.7 thousand for thethree months ended* December 31, 2023and2022*, respectively and $50.1 thousand and $274.0 thousand for thesix months ended* December 31, 2023and2022*, respectively. As of* December 31, 2023* and* June 30, 2023*, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $1.0 million and $1.6 million, respectively.

Note11 - Long-term Debt

Avenue Capital Loan

On* January 26, 2022 (“Closing Date”), the Company entered into a Loan and Security Agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture Opportunities Fund II, L.P. (Avenue2”) as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”, and collectively with the Avenue Capital Lenders, “Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025.*The proceeds from the Avenue Capital Agreement were used to repay the senior secured term credit facility with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P., which the Company assumed through the Neos Acquisition.

Pursuant to the Avenue Capital Agreement, the Company made interest only payments for thefirst 18 months following the Closing Date (“Interest-only Period”). In* June 2023,*the Company achieved certain defined milestones extending the Interest-Only Period through the maturity date.

In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i)2.0% of the loan if such event occurs after* January 26, 2023but on or before January 26, 2024,and (ii)1.0% of the loan if such event occurs after January 26, 2024but before January 26, 2025.*In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.

The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with afirst priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and asecond priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.

The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of* December 31, 2023*, the Company was in compliance with the covenants under the Avenue Capital Agreement.

On* January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022,the exercise price would be adjusted to the effective price of such equity offering, and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027.The Company accounted for the Avenue Capital Warrants as a liability as the number of warrants wasnot* fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.

19

On* March 7, 2022,the Company closed on an equity offering of shares of common stock and warrants at an offering price of $25.00 per share. As the Avenue Capital Agreement precluded the Company from pursuing any equity financing prior to July 7, 2022,and the effective price of the March 7, 2022*offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 43,388 at an exercise price of $24.20.

On* October 25, 2022,the Company entered into an agreement with Avenue to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022,extends the interest-only period to Januaryof2024.* In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s* August 2022*equity financing.

In addition to the debt discount discussed above, the Company incurred $0.4 million in loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 19.6%. Total interest expense, including debt discount amortization, was $0.7 million for both thethree months ended* December 31, 2023and2022*, and $1.5 million and $1.3 million for thesix months ended* December 31, 2023and2022*, respectively.

Long-term debt consists of the following:

Future principal payments of long-term debt, including financing leases, are as follows:

Note12 - Fair Value Considerations

The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishesthree levels of inputs that* may*be used to determine fair value as follows:

20

The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on the unaudited consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on the unaudited consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There wereno transfers between Level1, Level2, and Level3 in the periods presented.

Recurring Fair Value Measurements

The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of* December 31, 2023* and* June 30, 2023*, by level within the fair value hierarchy.

Summary of Level3 Input Changes**

The following table sets forth a summary of changes to those fair value measures using Level3 inputs for thesix months ended* December 31, 2023*.

21

Significant Assumptions

The following table presents the valuation methodologies and key assumptions used for the marked to market fair value measurements of derivative warrant liabilities as of* December 31, 2023*.

* Includes August 2022 Warrants, March 2022 Warrants, and Avenue Capital Warrants.

The Black-Scholes option pricing model is used to value all warrants with significant Level3 inputs. The Monte Carlo Simulation is used to simulate the exit price and EBITDA forecast; average warrant value per share is from100,000 Monte Carlo simulations. The Monte Carlo is based on significant inputs including financial projections provided by the Company’s management used primarily to forecast future resultsnot observable in the market, and thus, represents a Level3 measure.

Note13 - Commitments and Contingencies

Pediatric Portfolio Fixed Payments and Product Milestone

The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell Karbinal ER in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales.

The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from* August1* through* July31,* of 70,000 units annually through2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000‑unit annual minimum sales commitment through2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in* Augustof each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, thefirst* of which is triggered at $40.0 million of product net revenues.

Rumpus Earn Out Payments

On* April 12, 2021,the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating toAR101.* Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company made a payment of $0.6 million for a license fee in* April 2022.In addition, upon the achievement of regulatory and commercial milestones, the Company maybe required to pay up to $101.7 million and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. In October 2022,the Company announced the indefinite suspension of its development ofAR101.*

22

Legal Matters

Witmer Class-Action Securities Litigation.A stockholder derivative suit filed on September 12, 2022,in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, and later amended, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice’s Chief Investment Officer and Managing Partner, and a former director of Aytu) (collectively “Armistice”), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr, Carl Dockery and Ketan B. Mehta. The amended complaint alleges that (i) Armistice facilitated the sale of assets of Cerecor, Inc., in2019 and Innovus Pharmaceuticals, Inc., in2020 to Aytu in exchange for convertible securities, which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants’ breaches of fiduciary duties, in connection with these acquisitions. The amended complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys’ fees. While the Company believes that this lawsuit is without merit and has vigorously defended against it, the Company has agreed to settle the matter, as against it and the director defendants other than Mr. Boyd, for various corporate governance modifications and the payment of plaintiff’s attorneys’ fees. That settlement is subject to court approval, the hearing on which hasnot yet been scheduled.

Sabby Litigation. A complaint was filed on* February 22, 2023,in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund Ltd (“Sabby”) and Walleye Opportunities Master Fund Ltd (“Walleye”), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders mayreceive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In October 2023,*the Company entered into a settlement agreement and general release with Sabby and Walleye.

Stein Litigation. Cielo Stein (“Stein”), a former sales specialist, filed a complaint on* February 1, 2023,in Jefferson County Circuit Court in Kentucky against the Company and its wholly owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company’s response to Stein’s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys’ fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which was denied. The case has been referred to a magistrate judge for, among other things, the entry of a scheduling order and to conduct a settlement conference. Due to the early stage of litigation, and while the Company believes that this lawsuit is without merit, the Company isnot* able to predict at this time whether this proceeding will have a material impact on its financial condition or results of operations and intend to vigorously defend this case in the event it isnot dismissed.

Note14 - Capital Structure

The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. Included in the common stock outstanding are 40,017 shares of unvested restricted stock issued to executives, directors and employees.

On* June 8, 2020,the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020.This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the“2020* Shelf”). On* June 4, 2021,the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the2020* Shelf (the “ATM Sales Agreement”). During the year ended* June 30, 2023*, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. The2020 Shelf expired in* June 2023.*

23

On* September 28, 2021,the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021.This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the“2021* Shelf”). As of* December 31, 2023*, approximately $82.4 million remained available under the2021 Shelf. This availability is subject to SEC1.B.6 limitation to the Form S-3.

On* August 11, 2022,the Company closed on an underwritten public offering (the “August 2022Offering”) utilizing the2021* Shelf, pursuant to which it sold an aggregate of (i)1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, withone common warrant to purchaseone share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in* August 2022.The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period offive years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders’ equity in the Company’s consolidated financial statements (SeeNote16 – Warrants*).

On* June 8, 2023,using a placement agency, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i)1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants maybe exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant is exercisable forone share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable and maybe exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i)five years after the date of issuance, and (ii)30 days following the closing price of the Company’s common stock equaling200%* of the exercise price ($3.18 per share) for at least40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x)five years after the date of issuance, and (y)30 days following the Company’s achievement of consolidated trailingtwelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (SeeNote16* – Warrants*).

24

Note15 - Equity Incentive Plans

2023 Equity Incentive Plan. On* May 18, 2023,the Company’s stockholders approved the Aytu BioPharma, Inc.2023 Equity Incentive Plan (the“2023* Equity Incentive Plan”). Prior to the Company’s adoption of the2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc.2015 Stock Option and Incentive Plan (the “Aytu2015 Plan”) and the Neos Therapeutics, Inc.2015 Stock Options and Incentive Plan (the “Neos2015 Plan”, and collectively with the Aytu2015 Plan, the*“2015* Plans”). For the2023 Equity Incentive Plan, the stockholders approved (a)200,000 new shares, (b)87,129 shares available for grant under the2015 Plans be “rolled over” to the2023 Equity Incentive Plan and (c) any shares that are returned to the company under the2015 Plans be added to the2023 Equity Incentive Plan. With the approval of the2023 Equity Incentive Plan,no additional awards will be granted under the2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of* December 31, 2023*, the Company had 179,732 shares that are available for grant under the2023 Equity Incentive Plan.

Aytu2015* Plan.* On* June1,* 2015, the Company’s stockholders approved the Aytu2015 Plan, which, as amended in* July2017,* provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu2015 Plan will be added back to the shares of common stock available for issuance under the2023 Equity Incentive Plan. On* February**13,* 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, whereas the restricted stock units have a vesting period of 4 years.

Neos2015* Plan.* Pursuant to the Neos Merger, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos2015 Plan. Accordingly, on* April**19,* 2021, the Company registered 5,272 shares of its common stock under the Neos2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.

Stock Options

Stock option activity is as follows:

25

The weighted-average grant date fair value of options granted during thesix months ended* December 31, 2023* was $1.73. As of* December 31, 2023*, there was $0.4 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.85 years.

Restricted Stock

Restricted stock activity is as follows:

As of* December 31, 2023*, there was $2.0 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9 years.

As of* December 31, 2023*, there was $0.3 million total unrecognized costs related to non-vested restricted stock outside of the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.1 years. As of* December 31, 2023*,2,088 shares of restricted stock remain unvested.

Restricted Stock Units

Restricted stock units (“RSU” or “RSUs”) activity is as follows:

As of* December 31, 2023*, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.2 years.

26

Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:

Note16 - Warrants

Liability Classified Warrants

On* June 8, 2023,the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued and sold an aggregate of (i)1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The Tranche A Warrants and Tranche B Warrants maybe exercised for either shares of common stock or pre-funded exchange warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. Each pre-funded warrant is exercisable forone share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and maybe exercised at any time until all of the pre-funded warrants are exercised in full. The Tranche A Warrants and Tranche B Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per pre-funded exchange warrant). The Tranche A Warrants will expire upon the earlier of (i)five years after the date of issuance, and (ii)30 days following the closing price of the Company’s common stock equaling200%* of the exercise price ($3.18 per share) for at least40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x)five years after the date of issuance, and (y)30 days following the Company’s achievement of consolidated trailingtwelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million (seeNote14* – Capital Structure*).

On* August 11, 2022,the Company closed an offering (the “August 2022Offering”), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, whichone* common warrant to purchaseone share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in* August 2022.The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period offive years from issuance. The common warrants provide that if there occurs any stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of thefive* lowest trading days during the20 consecutive trading day period ending immediately preceding the16th trading day after such Stock Combination Event, divided by (y) five; or $2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to thesecond anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (seeNote14* – Capital Structure*).

In* November 2022and throughout the quarter ended December 31, 2022,the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On January 6, 2023,the Company consummated a 20 to1* reverse stock split. Pursuant to the warrant agreement described above, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowestfive trading days during thetwenty-day consecutive trading day period beginning on* December 30, 2022.Subsequently, as a result of the Securities Purchase Agreement in June 2023,the common warrants from the August 2022*Offering had an adjusted exercise price of $2.32.

27

Certain outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (seeNote12* – Fair Value Considerations*).

A summary of warrants is as follows:

Note17 - Earnings Per Share

Basic loss per common share is calculated by dividing the net loss available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company.

The following table sets forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share.

Note18 - License Agreements

Teva

On* December 21, 2018,Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026,*or earlier under certain circumstances.

Actavis

On* October 17, 2017,Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis (now Teva, following Teva’s acquisition of Actavis’ generic products) has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025,*or earlier under certain circumstances.

28

Note19 - Segment Reporting

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on the Company’s financial information. The CODM reviews financial information presented for each reportable segment for the purpose of making operating decisions and assessing financial performance.

The Company manages and aggregates its operational and financial information in accordance withtwo reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM doesnot regularly review asset information by segment, accordingly, asset information isnot provided by segment.

Select financial information for these segments is as follows:

29